New device could cut stroke risk in kidney patients on dialysis
NCT ID NCT07257614
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests a procedure called left atrial appendage occlusion (LAAO) using the Watchman Flx PRO device in 40 dialysis patients with atrial fibrillation. The goal is to see if it safely reduces stroke and major bleeding compared to standard care. Participants will be followed for one year to track outcomes like stroke, bleeding, and device success.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Watchman Flx PRO device
- What this could lead to
- If successful, this could offer a safer stroke prevention option for dialysis patients with atrial fibrillation, reducing bleeding risks compared to standard blood thinners.
- What could go wrong
- This is a small pilot study with only 40 participants, so results may not apply broadly. The procedure carries risks like bleeding or device complications, and long-term benefits are unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Chinese Universityy of Hong Kong
Shatin, New Territories, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can video games and electric pulses ease dialysis Patients' shoulder pain?
- A tiny neck implant could catch Stroke-Causing clots before they reach the brain
- A pill vs. a shot: which eases Kidney-Related anemia better?
- Could a new injection tame atrial fibrillation?
- Which blood thinner is safer for heart patients? a Head-to-Head test
- Can a cholesterol drug keep atrial fibrillation at bay after ablation?